Aktuelle Dermatologie 2005; 31(5): 225-232
DOI: 10.1055/s-2005-861183
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Photodynamische Therapie bei aktinischen Keratosen und Morbus Bowen

Photodynamic Therapy for Actinic Keratoses and Bowen's DiseaseS.  Radakovic-Fijan1 , H.  Hönigsmann1 , A.  Tanew1
  • 1Abteilung für Spezielle Dermatologie und Umweltdermatosen, Universitätsklinik für Dermatologie, Allgemeines Krankenhaus der Stadt Wien/Österreich
Further Information

Publication History

Publication Date:
25 May 2005 (online)

Zusammenfassung

Die photodynamische Therapie mit topisch applizierter Aminolävulinsäure wurde vor mehr als einem Jahrzehnt zur Behandlung oberflächlicher kutaner Neoplasien in die Dermatologie eingeführt. In der Zwischenzeit liegen zahlreiche klinische Studien an Patienten mit aktinischen Keratosen und Morbus Bowen vor, welche die Wirksamkeit und hervorragenden kosmetischen Ergebnisse dieser neuen Therapieform dokumentieren. In Abhängigkeit von Zahl, Ausprägung und Lokalisation können langzeitige Remissionsraten von bis zu 90 % erzielt werden, weshalb die photodynamische Therapie heutzutage zu den vorrangigen Behandlungsoptionen für multiple aktinische Keratosen und Morbus Bowen gehört.

Abstract

In the early 90's photodynamic therapy with topically applied aminolevulinic acid has been introduced in dermatology as a new treatment modality for superficial skin tumors. Since that time numerous studies on patients with actinic keratosis and Bowen's disease have demonstrated the efficacy and excellent cosmetic results of this new therapeutic principle. Depending on number, severity and localization response rates of up to 90 % can be achieved. Therefore PDT is nowadays considered as one of the first line treatments for multiple actinic keratoses and Bowen's disease.

Literatur

  • 1 Olsen E A, Abernethy M L, Kulp-Shorten C, Callen J P, Glazer S D, Huntley A, McCray M, Monroe A B, Tschen E, Wolf J E, Jr. A double-blinded, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head und neck.  J Am Acad Dermatol. 1991;  24 738-743
  • 2 Jeffes E WB, Tang E H. Actinic keratosis. Current treatment options.  Am J Clin Dermatol. 2000;  1 167-179
  • 3 Fritsch C, Goerz G, Ruzicka T. et al . Photodynamic therapy in dermatology.  Arch Dermatol. 1998;  134 207-214
  • 4 Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology.  J Am Acad Dermatol. 2000;  42 389-416
  • 5 Kennedy J C, Pottier R H, Pross D C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience.  J Photochem Photobiol B: Biol. 1990;  6 43-148
  • 6 Harth Y, Hirshowitz B, Kaplan B. Modified topical photodynamic therapy of superficial skin tumors, utilizing aminolevulinic acid, penetration enhancers, red light, and hyperthermia.  Dermatol Surg. 1998;  24 723-726
  • 7 Fijan S, Hönigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine.  Br J Dermatol. 1995;  133 282-288
  • 8 Varma S, Wilson H, Kurwa H A. et al . Bowen`s disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source.  Br J Dermatol. 2001;  144 567-574
  • 9 Szeimies R M, Karrer S, Sauerwald A, Landthaler M. Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study.  Dermatology. 1996;  192 246-251
  • 10 Fink-Puches R, Hofer A, Smolle J, Kerl H, Wolf P. Primary clinical response and long-term follow-up of solar keratoses treated with topically applied 5-aminolevulinic acid and irradiation by different wave bands of light.  J Photochem Photobiol B: Biol. 1997;  41 145-151
  • 11 Fritsch C, Stege H, Saalmann G. et al . Green light is effective and less painful than red light in photodynamic therapy of facial solar keratoses.  Photodermatol Photoimmunol Photomed. 1997;  13 181-185
  • 12 Jeffes E W, McCullough J L, Weinstein G D. et al . Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light.  J Am Acad Dermatol. 2001;  45 96-104
  • 13 Calzavara-Pinton P G. Repetitive photodynamic therapy with topical ς-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours.  J Photochem Photobiol B: Biol. 1995;  29 53-57
  • 14 Jeffes E W, McCullough J L, Weinstein G D. et al . Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study.  Arch Dermatol. 1997;  133 727-732
  • 15 Karrer S, Bäumler W, Abels C. et al . Long-pulse dye laser for photodynamic therapy: investigations in vitro and in vivo.  Lasers Surg Med. 1999;  25 51-59
  • 16 Szeimies R M, Karrer S, Radakovic-Fijan S. et al . Photodynamic therapy using topical methyl-5-aminolevulinate (Metvix) is as efficacious as cryotherapy in actinic keratosis, but with superior cosmetic results and high patient satisfaction.  J Am Acad Dermatol. 2002;  47 258-262
  • 17 Freeman M, Vinciullo C, Francis D. et al . A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study.  J Dermatolog Treat. 2003;  14 99-106
  • 18 Pariser D M, Lowe N J, Stewart D M. et al . Photodynamic thaerapy with topical methyl aminolevulinate for actinic keratosis: Results of a prospective randomized multicenter trial.  J Am Acad Dermatol. 2003;  48 227-232
  • 19 Kurwa H A, Yong-Gee S A, Seed P T, Markey A C, Barlow R J. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses.  J Am Acad Dermatol. 1999;  41 414-418
  • 20 Morton C A, Brown S B, Collins S. et al . Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group.  Br J Dermatol. 2002;  146 552-567
  • 21 Thestrup-Pederson K, Ravnborg L, Reymann F. Morbus Bowen. A description of disease in 617 patients.  Acta Derm Venerol (Stockh). 1988;  68 236-239
  • 22 Bell H K, Rhodes L E. Bowen`s disease - a retrospective review of clinical management.  Clin Exp Dermatol. 1999;  24 336-339
  • 23 Cox N H, Eedy D J, Morton C A. Guidelines for management of Bowen`s disease.  Br J Dermatol. 1999;  141 633-641
  • 24 Morton C A. Topical sensitisation - oncologic indications - Bowen`s disease. In: Calzavara-Pinton P, Szeimies RM, Ortel B Photodynamic therapy and fluorescence diagnosis in dermatology. Amsterdam; Elsevier 2001: 217-234
  • 25 Robinson P J, Carruth J AS, Fairris G M. Photodynamic therapy: a better treatment for widespread Bowen`s disease .  Br J Dermatol. 1988;  119 59-61
  • 26 Jones C M, Mang T, Cooper M, Wilson D, Stoll H L. Photodynamic therapy in the treatment of Bowen`s disease.  J Am Acad Dermatol. 1992;  27 979-982
  • 27 Waldow S M, Lobraico R V, Kohler I K, Wallk S, Fritts H T. Photodynamic therapy for treatment of malignant cutaneous lesions.  Lasers Surg Med. 1987;  7 451-456
  • 28 Buchanan R B, Carruth J AS, McKenzie A L, Williams S R. Photodynamic therapy in the treatment of malignant tumours of the skin and head and neck.  Eur J Surg Oncol. 1989;  15 400-406
  • 29 Petrelli N J, Cebollero J A, Rodriguez-Bigas M, Mang T. Photodynamic therapy in the management of neoplasms of the perianal skin.  Arch Surg. 1992;  127 1436-1438
  • 30 Wolf P. Photodynamische Therapie (PDT).  Hautarzt. 1997;  48 137-148
  • 31 Svanberg K, Andersson T, Killander D. et al . Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-aminolevulinic acid sensitization and laser irradiation.  Br J Dermatol. 1994;  130 743-751
  • 32 Morton C A, Whitehurst C, Moseley H, Moore J V, MacKie R M. Development of an alternative light source to lasers for photodynamic therapy: 3. Clinical evaluation in the treatment of pre-malignant non-melanoma skin cancer.  Lasers Med Sci. 1995;  10 165-171
  • 33 Stables G I, Stringer M R, Robinson D J, Ash D V. Large patches of Bowen's disease treated by topical aminolaevulinic acid photodynamic therapy.  Br J Dermatol. 1997;  136 957-960
  • 34 Morton C A, Whitehurst C, McColl J H, Moore J V, MacKie R M. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma.  Arch Dermatol. 2001;  137 319-324
  • 35 Morton C A, Whitehurst C, Moore J V, MacKie R M. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy.  Br J Dermatol. 2000;  143 767-772
  • 36 Cairnduff F, Stringer M R, Hudson E J, Ash D V, Brown S B. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer.  Br J Cancer. 1994;  69 605-608
  • 37 Sacchini V, Melloni E, Marchesini R. et al . Topical administration of tetrasodium-meso-tetraphenyl-porphinesulfonate (TPPS) and red light irradiation for the treatment of superficial neoplastic lesions.  Tumori. 1987;  73 19-23
  • 38 Morton C A, Whitehurst C, Moseley H. et al . Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease.  Br J Dermatol. 1996;  135 766-771
  • 39 Salim A, Leman J A, McColl J H, Chapman R, Morton C A. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease.  Br J Dermatol. 2003;  148 539-543

Prof. Dr. Adrian Tanew

Abteilung für Spezielle Dermatologie und Umweltdermatosen, Universitätsklinik für Dermatologie, Allgemeines Krankenhaus der Stadt Wien

Währinger Gürtel 18-20 · 1090 Wien · Österreich

Email: adrian.tanew@meduniwien.ac.at

    >